President Trump continues to make tough decisions as he navigates his presidency. This time President Trump is taking historic action to move pharmaceutical manufacturing out of China.
According to The Daily Wire:
“Seeking to secure the nation’s supply of critical medications, the Trump administration has signed a $354 million contract that would create the nation’s first strategic stockpile of key ingredients needed to make medicines,” NBC News reported. “The agreement was signed Monday with Phlow Corp., a generic drug maker based in Virginia.”
White House Trade Adviser Peter Navarro, a staunch China hawk who is the mastermind behind President Donald Trump’s trade war with the communist nation, said that the move “will not only help bring our essential medicines home but actually do so in a way that is cost competitive with the sweatshops and pollution havens of the world.”
Navarro added, “This is an historic turning point in America’s efforts to onshore its pharmaceutical production and supply chains.”
The New York Times reported that the company could see the contract “extended for a total of $812 million over 10 years, making it one of the largest awards in” the history of the Biomedical Advanced Research and Development Authority (BARDA).
Dr. Eric Edwards, the chief executive and president of Phlow, said in an interview with The New York Times, “There are not a lot of people wanting to bring back generic medicine manufacturing to the United States that has been lost to India and China over decades. You need someone like the federal government saying this is too important for us not to focus on.”
Phlow Corp lists itself as an America First company and a move like this adds more evidence to the truth of that statement.